Evidence map›Paper›PMID 27529127›Full record

ArticleeLife2016

A Cryptochrome 2 mutation yields advanced sleep phase in humans.

Arisa Hirano, Guangsen Shi, Christopher R Jones, Anna Lipzen, Len A Pennacchio, Ying Xu, William C Hallows, Thomas McMahon, Maya Yamazaki, Louis J Ptáček and 1 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 169 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Emerging genetics of sleep and circadian disorders.Current opinion in pediatrics · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Targeting Cryptochromes in Chronic Diseases.Cell biology international · 2025
    Review
  10. Review
  11. Article
  12. Rare variants inProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  13. Article
  14. Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Arisa HiranoDepartment of Neurology, University of California, San Francisco, San Francisco, United States.
Guangsen ShiDepartment of Neurology, University of California, San Francisco, San Francisco, United States.
Christopher R JonesDepartment of Neurology, University of Utah, Salt Lake City, United States.
Anna LipzenLawrence Berkeley National Laboratory, Berkeley, United States.
Len A PennacchioLawrence Berkeley National Laboratory, Berkeley, United States.
Ying XuCenter for System Biology, Soochow University, Suzhou, China.ORCID 0000-0002-6689-7768
William C HallowsDepartment of Neurology, University of California, San Francisco, San Francisco, United States.ORCID 0000-0001-8306-8438
Thomas McMahonDepartment of Neurology, University of California, San Francisco, San Francisco, United States.
Maya YamazakiDepartment of Neurology, University of California, San Francisco, San Francisco, United States.
Louis J PtáčekDepartment of Neurology, University of California, San Francisco, San Francisco, United States.
Ying-Hui FuDepartment of Neurology, University of California, San Francisco, San Francisco, United States.ORCID 0000-0002-6628-0266
University of California, San Francisco · USLawrence Berkeley National Laboratory · USHoward Hughes Medical Institute · USSoochow University · CNUniversity of Utah · US

Funding

Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRUMMEL, MATTHEW F · 2003 to 2019
$21.8M
GENETICS AND MOLECULAR CHARACTERIZATION OF ASPSR01HL059596 · NHLBI · UNIVERSITY OF UTAH · PI PTACEK, LOUIS J. · 1997 to 2012
$5.2M
A chemical genetic approach to dissect CKId & CKIe function in circadian rhythmR01GM079180 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FU, YING-HUI · 2008 to 2011
$1.3M
NHLBI NIH HHS R01 HL059596NIDDK NIH HHS P30 DK063720NIGMS NIH HHS R01 GM079180
6 · The paper itself

Abstract

Familial Advanced Sleep Phase (FASP) is a heritable human sleep phenotype characterized by very early sleep and wake times. We identified a missense mutation in the human Cryptochrome 2 (CRY2) gene that co-segregates with FASP in one family. The mutation leads to replacement of an alanine residue at position 260 with a threonine (A260T). In mice, the CRY2 mutation causes a shortened circadian period and reduced phase-shift to early-night light pulse associated with phase-advanced behavioral rhythms in the light-dark cycle. The A260T mutation is located in the phosphate loop of the flavin adenine dinucleotide (FAD) binding domain of CRY2. The mutation alters the conformation of CRY2, increasing its accessibility and affinity for FBXL3 (an E3 ubiquitin ligase), thus promoting its degradation. These results demonstrate that CRY2 stability controlled by FBXL3 plays a key role in the regulation of human sleep wake behavior.

Indexed as

Mutation, MissenseAlanineAmino Acid SubstitutionAnimalsCryptochromesF-Box ProteinsHumansMiceMutant ProteinsProtein ConformationProteolysisSleep Disorders, Circadian RhythmThreonineUbiquitinationAlanineCRY2 protein, humanCryptochromesF-Box ProteinsFBXL3 protein, humanMutant ProteinsThreoninecircadian clockcircadian rhythmcryptochrome2Familial Advanced Sleep PhaseFBXL3humanhuman biologymedicinemouseneuroscience

Identifiers

PMID27529127
PMCPMC5398888
OpenAlexW2516332895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.